Brachytherapy: Increased Use in Patients With Intermediate- and High-Risk Prostate Cancers

Clin J Oncol Nurs. 2021 Jun 1;25(3):321-328. doi: 10.1188/21.CJON.321-328.

Abstract

Background: Brachytherapy is a well-established and effective primary treatment modality for low- and favorable intermediate-risk prostate cancers. Although the benefits of brachytherapy in unfavorable intermediate- and high-risk prostate cancers have not been as clear, research suggests that brachytherapy boost may improve biochemical progression-free survival in these patients.

Objectives: This article aims to discuss evidence for the revival of brachytherapy use in unfavorable intermediate- and high-risk prostate cancers and specific nursing implications in the management of these patients.

Methods: The literature on brachytherapy and its use to treat localized prostate cancers was reviewed.

Findings: Nurses should be knowledgeable about the indications for brachytherapy, patient eligibility, anticipated side effects, and symptom management.

Keywords: brachytherapy; cancer risk; localized prostate cancer; prostate cancer; radiation therapy.

MeSH terms

  • Brachytherapy*
  • Humans
  • Male
  • Prostate-Specific Antigen
  • Prostatic Neoplasms* / radiotherapy
  • Radiotherapy Dosage
  • Treatment Outcome

Substances

  • Prostate-Specific Antigen